Short sellers ramped up positions ahead of BMRN's Q1 print. Options traders show strong call bias, suggesting near-term bullish sentiment despite the bearish positioning.
Short interest stands at 8.97 million shares, or 4.67% of free float.
That's up 8.3% over the past month. The climb accelerated in early April, with shares borrowed rising from 8.46 million on April 8 to current levels.
Days to cover sits at 4.2 based on recent volume. The ORTEX short score is 39.7, reflecting moderate short conviction relative to the broader biotech universe.
Put-call ratio crashed to 0.39 on April 23, the lowest reading in a year.
The 20-day average PCR is 0.51, with a standard deviation of 0.06. The current PCR sits nearly two standard deviations below that mean, signaling unusually heavy call buying.
PCR hovered near 0.59 in late March before collapsing this week. The shift points to near-term optimism heading into the report.
No analyst rating changes or price target updates are available in the snapshot.
Institutional ownership and consensus data are unavailable at this time.
BioMarin last reported on February 23, 2026. The company announced that print on February 17, giving investors a week's notice.
Prior earnings dates include October 27, 2025. Historical price reactions to past prints are not included in the data.
No active ORTEX Alpha signals are present for BioMarin.
No signals have triggered recently. The stock trades at $53.98, down 0.3% Wednesday and off 1.5% over the past month.
Cost to borrow sits at 0.31%, down 21% over the past week. Utilization is 0.5%, well below the 52-week high of 1.45%.
See the live data behind this article on ORTEX.
Open BMRN on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
